文献速递角膜与眼表疾病眼整形与眼眶

结膜浸润性鳞状细胞癌的管理与预后

Management of Invasive Squamous Cell Carcinomas of the Conjunctiva.
PubMed 文献 · Am J Ophthalmol · 2018-12-12

该回顾性病例系列纳入2002至2017年组织学证实的结膜浸润性微浸润鳞状细胞癌(miSCC,浸润≤0.2 mm)或鳞状细胞癌(SCC)连续患者,比较其临床特征、治疗与结局。结果显示miSCC局部复发率略高于SCC,术后质子治疗仅用于SCC并与较低复发风险相关。

要点

  • miSCC局部复发率略高于SCC(24个月发生率20% vs 12%),但差异未达统计学显著。
  • 质子治疗仅用于SCC(92.0%),与较低局部复发风险独立相关(HR 0.25)。
  • 丝裂霉素在miSCC中更常用(93.3% vs 20.5%),SCC则在切缘阳性时使用。

核心结论

  • 微浸润结膜鳞状细胞癌的局部复发率略高于浸润性鳞状细胞癌。
  • 术后质子治疗仅在浸润性鳞状细胞癌中实施,并与较低的局部复发风险相关。

研究设计与样本

  • 回顾性病例系列,纳入2002至2017年组织学证实的结膜浸润性miSCC或SCC连续患者。

主要发现

  • 患者70%为男性,56%年龄≥70岁,83.0%肿瘤位于球结膜。
  • 角膜缘、角膜和/或巩膜受累分别占70.4%、42.6%和27.8%。
  • miSCC与SCC的患者特征、肿瘤特征及无接触手术率相似。
  • 24个月局部复发发生率为14.8%,miSCC为20%、SCC为12%(P = .079)。
  • 发生2例癌症相关死亡(2%),轻/中度前节并发症见于三分之一患者。

关键数值与推荐

  • miSCC定义为肿瘤浸润脉络膜≤0.2 mm,超过者为SCC。
  • 丝裂霉素在miSCC和SCC中分别有93.3%和20.5%实施(P < .001)。
  • 质子治疗在miSCC和SCC中分别有0%和92.0%实施(P < .001)。
  • 放疗是与较低局部复发风险相关的唯一预后因素(风险比[0.25];P = .045)。

临床怎么用

  • 对结膜浸润性鳞状细胞癌应根据浸润深度区分miSCC与SCC并评估复发风险。
  • SCC患者可考虑术后质子治疗以降低局部复发风险。
  • miSCC患者更常辅以丝裂霉素治疗,SCC则在切缘阳性时使用。

局限性

  • 原文未报告随访时长、质子治疗选择偏倚等具体局限信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ocular surface squamous neoplasia includes a spectrum of diseases from dysplasia to invasive squamous cell carcinoma (SCC) of the conjunctiva. Whether the degree of invasion influences outcomes is debated. We evaluated the outcomes and management of conjunctival carcinomas defined as ≤0.2 mm invasion of the chorion (microinvasive; miSCC) or over (SCC). DESIGN: Retrospective case series. METHODS: Clinical, tumor, and therapeutic characteristics and outcomes were collected for consecutive patients with histology-proven invasive conjunctival miSCC/SCC treated between 2002 and 2017. RESULTS: Patients were 70% men, ≥70 years old (56%), with carcinomas of the bulbar conjunctiva (83.0%). Limbal, corneal, and/or scleral involvement were present in 70.4%, 42.6%, and 27.8%, respectively. Patient characteristics, tumor characteristics, and no-touch surgery rates were similar between the 39 SCC and 15 miSCC. However, mitomycin was performed in 93.3% and 20.5% of miSCC and SCC, respectively (P < .001). Proton therapy was performed in 0% and 92.0% of miSCC and SCC, respectively (P < .001). SCC received mitomycin in case of tumoral resection margins, respectively (P = .018). The 24-month incidence of local relapse was 14.8%, including 20% and 12% for miSCC and SCC, respectively (P = .079). Irradiation was the only prognostic factor associated with a lower risk for local relapse (hazard ratio [0.25]; P = .045). There were 2 cancer-related deaths (2%). Mild/moderate anterior segment complications occurred in one third of the patients. CONCLUSIONS: miSCC had slightly worse relapse rates compared with SCC. Postoperative proton therapy, performed in SCC only, was associated with a lower risk for relapse.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Santoni A, Thariat J, Maschi C, et al. Management of Invasive Squamous Cell Carcinomas of the Conjunctiva. Am J Ophthalmol. 2018. PMID: 30552889. doi:10.1016/j.ajo.2018.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。